South Korea · Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 1.85 trillion. The enterprise value is 1.88 trillion.
| Market Cap | 1.85T |
| Enterprise Value | 1.88T |
Important Dates
The next estimated earnings date is Friday, October 31, 2025.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
ST Pharm has 20.70 million shares outstanding. The number of shares has increased by 6.72% in one year.
| Current Share Class | 20.70M |
| Shares Outstanding | 20.70M |
| Shares Change (YoY) | +6.72% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 7.40% |
| Owned by Institutions (%) | 6.58% |
| Float | 12.97M |
Valuation Ratios
The trailing PE ratio is 53.07 and the forward PE ratio is 35.62.
| PE Ratio | 53.07 |
| Forward PE | 35.62 |
| PS Ratio | 6.21 |
| PB Ratio | 3.70 |
| P/TBV Ratio | 3.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 26.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.15, with an EV/FCF ratio of -234.19.
| EV / Earnings | 55.43 |
| EV / Sales | 6.31 |
| EV / EBITDA | 27.15 |
| EV / EBIT | 44.19 |
| EV / FCF | -234.19 |
Financial Position
The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.18 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | -14.73 |
| Interest Coverage | 5.53 |
Financial Efficiency
Return on equity (ROE) is 6.94% and return on invested capital (ROIC) is 4.44%.
| Return on Equity (ROE) | 6.94% |
| Return on Assets (ROA) | 3.83% |
| Return on Invested Capital (ROIC) | 4.44% |
| Return on Capital Employed (ROCE) | 7.32% |
| Revenue Per Employee | 455.13M |
| Profits Per Employee | 51.81M |
| Employee Count | 655 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.18 |
Taxes
In the past 12 months, ST Pharm has paid 10.61 billion in taxes.
| Income Tax | 10.61B |
| Effective Tax Rate | 24.78% |
Stock Price Statistics
The stock price has decreased by -9.78% in the last 52 weeks. The beta is 0.43, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -9.78% |
| 50-Day Moving Average | 93,128.00 |
| 200-Day Moving Average | 84,317.00 |
| Relative Strength Index (RSI) | 44.20 |
| Average Volume (20 Days) | 195,495 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 298.11 billion and earned 33.94 billion in profits. Earnings per share was 1,686.44.
| Revenue | 298.11B |
| Gross Profit | 110.27B |
| Operating Income | 42.82B |
| Pretax Income | 42.82B |
| Net Income | 33.94B |
| EBITDA | 69.53B |
| EBIT | 42.82B |
| Earnings Per Share (EPS) | 1,686.44 |
Balance Sheet
The company has 89.13 billion in cash and 118.30 billion in debt, giving a net cash position of -29.17 billion or -1,409.22 per share.
| Cash & Cash Equivalents | 89.13B |
| Total Debt | 118.30B |
| Net Cash | -29.17B |
| Net Cash Per Share | -1,409.22 |
| Equity (Book Value) | 500.45B |
| Book Value Per Share | 24,860.55 |
| Working Capital | 174.89B |
Cash Flow
In the last 12 months, operating cash flow was 70.63 billion and capital expenditures -78.66 billion, giving a free cash flow of -8.03 billion.
| Operating Cash Flow | 70.63B |
| Capital Expenditures | -78.66B |
| Free Cash Flow | -8.03B |
| FCF Per Share | -388.06 |
Margins
Gross margin is 36.99%, with operating and profit margins of 14.36% and 11.38%.
| Gross Margin | 36.99% |
| Operating Margin | 14.36% |
| Pretax Margin | 14.36% |
| Profit Margin | 11.38% |
| EBITDA Margin | 23.32% |
| EBIT Margin | 14.36% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.56%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.56% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 29.69% |
| Buyback Yield | -6.72% |
| Shareholder Yield | -6.16% |
| Earnings Yield | 1.83% |
| FCF Yield | -0.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 5.72 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.72 |
| Piotroski F-Score | 6 |